No Patient or Illness to be Treated? The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca)

Vedder, H., 2015, In : Journal of European Competition Law & Practice. 6, 9, p. 664-668 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard


  • Journal_of_European_Competition_Law_Practice_2015_Vedder_jeclap_lpv057

    Final publisher's version, 73.5 KB, PDF document

    Request copy


This article discusses the decision of the netherlands competition authority in the AstraZeneca case and puts this in a broader perspective of regulation in the pharmaceutical market, price regulation and responses to market failures.
Original languageEnglish
Pages (from-to)664-668
Number of pages5
JournalJournal of European Competition Law & Practice
Issue number9
Early online date25-Aug-2015
Publication statusPublished - 2015


  • Pharmaceutical markets, competition law

ID: 23268620